Compare AU

Compare CURE vs. EMKT

Compare shares and ETFs on the ASX that you can trade on Pearler.

S&P US Biotech

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the S&P US Biotech (CURE) and the MSCI Emerging Markets Shares (EMKT). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

EMKT

Popularity

Low

Low

Pearlers invested

82

156

Median incremental investment

$619.50

$1,028.59

Median investment frequency

Monthly

Monthly

Median total investment

$1,325.00

$3,300.98

Average age group

> 35

> 35


Key Summary

CURE

EMKT

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

EMKT.AX was created on 2018-04-10 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 163.18m in AUM and 204 holdings. The VanEck MSCI Multifactor Emerging Markets Equity ETF (EMKT.AX) invests in a diversified portfolio of emerging markets listed securities with the aim of providing investment returns, before fees and other costs, which track the performance of the MSCI Emerging Markets Diversified MultipleFactor Index (AUD) (EMKT.AX Index).

Top 3 holdings

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

Taiwan Semiconductor Manufacturing Co Ltd (7.87 %)

HCL Technologies Ltd (2.63 %)

Tencent Holdings Ltd (2.49 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Information Technology (58.92 %)

Materials (12.51 %)

Energy (9.56 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

India (23.86 %)

Taiwan (23.66 %)

China (21.17 %)

Management fee

0.45 %

0.69 %


Key Summary

CURE

EMKT

Issuer

Global X

VanEck

Tracking index

S&P Biotechnology Select Industry

MSCI Emerging Markets Diversified Multiple-Factor Index - AUD

Asset class

ETF

ETF

Management fee

0.45 %

0.69 %

Price

$50.00

$25.89

Size

$36.301 million

$163.545 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

3.31 %

Market

ASX

ASX

First listed date

12/11/2018

12/04/2018

Purchase fee

$6.50

$6.50


Community Stats

CURE

EMKT

Popularity

Low

Low

Pearlers invested

82

156

Median incremental investment

$619.50

$1,028.59

Median investment frequency

Monthly

Monthly

Median total investment

$1,325.00

$3,300.98

Average age group

> 35

> 35


Pros and Cons

CURE

EMKT

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

  • Higher price growth

Cons

  • Lower price growth

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

CURE

EMKT

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home